esophageal neoplasm
Conditions
Interventions
docetaxel 70 mg/m2/day day1 iv cisplatin 70 mg/m2/day day1 iv 5-fluorouracil 750 mg/m2/day day1-5 civ q3w , 3 cycle 5-fluorouracil 700mg/m2/day day1-5 civ cisplatin 70mg/m2/day day1 RT 60Gy/30f
Sponsors
National Cancer Center Hospital East
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically proven squamous cell carcinoma or adenosquamous cell carcinoma of the esophagus 2) Primary lesion are located within the thoracic esophagus (Te) 3) radiologist permits curative radiotherapy 60Gy 4) with T4 tumors and/or distant lymph node metastasis (M1LYM) 5) no lymph nodes more distant than the celiac region in the abdomen/no distant organ metastases 6) no esophagobronchial fistulas/no esophagomediastinal fistulas, 7) Aged 20 to 70 years old 8) ECOG PS of 0 or 1 9) no previous treatment of esophageal cancer without endoscopic resection 10) no previous chemotherapy or radiotherapy against any other malignancies 11) adequate organ functions 12) written informed consent
Exclusion criteria
Exclusion criteria: 1) Simultaneous or metachronous (within 5 years) double cancers , with the exception of intramucosal tumor curable with local therapy 2) Pregnant or lactating women or women of childbearing potential 3) Psychosis 4) Patients requiring systemic steroids medication 5) HBs antigen positive 6) Uncontrollable diabetes millutus 7) History of myocardial infarction within three months 8) History of unstable angina pectoris or interstitial pneumonia or fibroid lung or severe emphysema 9) Active bacterial or fungous infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate | — |
Countries
Japan
Contacts
Public ContactHironaga SATAKE,MD
National Cancer Center Hospital East Division of Digestive Endoscopy and GI Oncology
Outcome results
None listed